Re: Locion alternativa [No demostrado cientificamente]
Publicado: Mié Abr 17, 2013 7:02 pm
Habemus escribió:Hello how are you!.
Y indometacina, ¿Y Que Tiene ESO con la que ver la alopecia androgenética?
Aprobado por qué organismo?
Lee esto,estudio por estudio Habemus si los entendes despues hablamos.
MPB as Inflammatory/Autoimmune Disorder
H-PGDS appears to be the main or only PGDS that could potentially play a role in the generation of local prostaglandins and induce androgenic alopecia. H-PGDS acts within a specialized type of immune cell called a mast cell to convert the downstream product of arachidonic acid (PGH2) into PGD2:
PGD(2) is formed from arachidonic acid by successive enzyme reactions: oxygenation of arachidonic acid to PGH(2), a common precursor of various prostanoids, catalyzed by cyclooxygenase, and isomerization of PGH(2) to PGD(2) by PGD synthases (PGDSs). PGD(2) can be either pro- or anti-inflammatory depending on disease process and etiology[6]
Mast cells exist in red blood cells, skin, the gastrointestinal tract, and the vascular system. Functioning mast cells are part of a normal, health immune system and also play roles in wound healing, but overactive mast cells are implicated in various immunological or inflammatory disorders as well as other diseases; PGD2 is a key component in some of these conditions:
Prostaglandin (PG)D(2) is a key mediator in various inflammatory diseases including allergy and asthma. It is generated by activated mast cells after allergen exposure and subsequently orchestrates the recruitment of inflammatory cells to the tissue. PGD(2) induces the chemotaxis of Th2 cells, basophils and eosinophils, stimulates cytokine release from these cells and prolongs their survival, and might hence indirectly promote IgE production. PGD(2) mediates its biologic functions via 2 distinct G protein-coupled receptors, D-type prostanoid receptor (DP), and the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) [7]
If Cotsarelis and Garza’s findings that PGD2 is a causative factor in human male pattern baldness are replicated, male pattern baldness may come to be regarded as an inflammatory or autoimmune disorder.
Citas
[1]Shichijo M, Inagaki N, Nakai N, Kimata M, Nakahata T, Serizawa I, Iikura Y, Saito H, Nagai H. The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin Exp Allergy. 1998 Oct;28(10):1228-36[2] Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L, Ahluwalia G, Fischer SM, FitzGerald GA, Cotsarelis G. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012 Mar 21;4(126):126ra34.
[3] Wei-Min Qu et al. Lipocalin-type prostaglandin D synthase produces prostaglandin D2 involved in regulation of physiological sleep. PNAS 103(47), 17949–17954. Nov 2006.
[4] Urade Y, Eguchi N. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:375-82.
[5] Al-Waili NS, Saloom KY, Al-Waili T, Al-Waili A, Al-Waili H. Modulation of prostaglandin activity, part 1: prostaglandin inhibition in the management of nonrheumatologic diseases: immunologic and hematologic aspects. Adv Ther. 2007 Jan-Feb;24(1):189-222.
[6] Joo M, Sadikot RT. PGD synthase and PGD2 in immune resposne (sic). Mediators Inflamm. 2012;2012:503128. Epub 2012 Jun 25.
[7]Schuligoi R, Sturm E, Luschnig P, Konya V, Philipose S, Sedej M, Waldhoer M, Peskar BA, Heinemann A. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology. 2010;85(6):372-82. Epub 2010 Jun 16.
Mas estudios sobre PGD
Colombe L et al. Prostaglandin metabolism in human hair follicle. Exp Derm. Vol 16, 9, p762–9, Sept 2007.
Wolf R, Matz H, Zalish M, Pollack A, Orion E. Prostaglandin analogs for hair growth: Great expectations. Dermatology Online Journal 9(3): 7
Kevin J. McElwee, PhD and Jerry Shapiro, MD, FRCPC. Promising Therapies for Treating and/or Preventing Androgenic Alopecia. Skin ther. Let.
Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol. 2002;82(1):7-12.
Griffin BW, Magnino PE, Pang IH, Sharif NA. Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J Pharmacol Exp Ther. 1998 Jul;286(1):411-8.
Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012 May;66(5):794-800. doi: 10.1016/j.jaad.2011.05.026. Epub 2011 Aug 27.
Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S185-202.
Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. 2005 May;14(5):323-8.
Walch et al. Prostaglandin (PG) FP and EP1 Receptors Mediate PGF2α and PGE2 Regulation of Interleukin-1β Expression in Leydig Cell Progenitors Endocrinology 144 (4): 1284. 4/2003.
